Annexin's CEO comments on Q2
24 juli, 10:05
24 juli, 10:05
The second quarter was a strategically important period for Annexin, with a focus on taking the next step in the development of ANXV and broadening the development to also include the eye disease diabetic retinopathy (DR). Annexin is currently awaiting approval from the UK Medicines Agency to be able to start a Phase IIa study with ANXV in DR and also newly diagnosed retinal vein occlusion (RVO) as part of the preparatory work for an upcoming Phase IIb study with the aim of evaluating a shorter treatment cycle than previously. In parallel, the company continues its focus on business development and discussions with potential partners for the continued development and commercialization of ANXV.
Read the full interview at biostock.se:
Annexin's CEO comments on Q2
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
24 juli, 10:05
The second quarter was a strategically important period for Annexin, with a focus on taking the next step in the development of ANXV and broadening the development to also include the eye disease diabetic retinopathy (DR). Annexin is currently awaiting approval from the UK Medicines Agency to be able to start a Phase IIa study with ANXV in DR and also newly diagnosed retinal vein occlusion (RVO) as part of the preparatory work for an upcoming Phase IIb study with the aim of evaluating a shorter treatment cycle than previously. In parallel, the company continues its focus on business development and discussions with potential partners for the continued development and commercialization of ANXV.
Read the full interview at biostock.se:
Annexin's CEO comments on Q2
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Handelskrig
Apple
Analys
Handelskrig
Apple
Analys
1 DAG %
Senast
Kempower
Igår, 12:28
Laddat för tillväxt i Kempower
OMX Stockholm 30
1 DAG %
Senast
2 533,59